<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02414230</url>
  </required_header>
  <id_info>
    <org_study_id>IND 123119 Protocol B</org_study_id>
    <nct_id>NCT02414230</nct_id>
  </id_info>
  <brief_title>F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis</brief_title>
  <acronym>T807ALS</acronym>
  <official_title>F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis (IND 123119 Protocol B)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tammie L. S. Benzinger, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate tau distribution in the brain of subjects&#xD;
      with: ALS caused by different genetic mutations, any mutation carriers (with or without&#xD;
      symptoms), any non-mutation carrier, any sporadic FTD, normal controls.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Actual">June 10, 2020</completion_date>
  <primary_completion_date type="Actual">September 19, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>F 18 T807 Standard Uptake Value Ratios (SUVR) will be correlated with other imaging modalities (MRI, PET amyloid imaging) and cognitive performance.</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">9</enrollment>
  <condition>Amyotrophic Lateral Sclerosis (ALS)</condition>
  <arm_group>
    <arm_group_label>Experimental F 18 T807</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: F 18 T807</intervention_name>
    <description>Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.</description>
    <arm_group_label>Experimental F 18 T807</arm_group_label>
    <other_name>Drug: 18F-AV-1451</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Collaborating neuromuscular physicians will refer participants for MR and PET imaging to&#xD;
        evaluate tau distribution in the brain of subjects with ALS, or ALS with frontotemporal&#xD;
        dementia caused by different genetic mutations, or any mutation carrier (with or without&#xD;
        symptoms), or normal controls.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female participants, at least 18 years of age.&#xD;
&#xD;
          2. Clinically diagnosed with amyotrophic lateral sclerosis (ALS), fronto-temporal&#xD;
             dementia (FTD), or both; or a carrier of a mutation known to cause ALS or FTD (with or&#xD;
             without symptoms); or a normal control.&#xD;
&#xD;
          3. Participant is able and willing to undergo testing (psychometric testing, MRI or CT,&#xD;
             PET, radioactive tracer injection; for those unable to undergo an MRI, CT will be used&#xD;
             to generate regions-of-interest).&#xD;
&#xD;
          4. Pre-menopausal women will undergo a urine pregnancy test within 24 hours of drug&#xD;
             administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has any condition that, in the Investigator's opinion, could increase risk to the&#xD;
             participant, limit the participant's ability to tolerate the experimental procedures,&#xD;
             or interfere with the collection/analysis of the data (for example, participants with&#xD;
             significant respiratory involvement may not be able to lie flat during the scanning&#xD;
             procedures).&#xD;
&#xD;
          2. Is deemed likely unable to perform the imaging procedures for any reason.&#xD;
&#xD;
          3. Has a high risk for Torsades de Pointes or is taking medications known to prolong QT&#xD;
             interval.&#xD;
&#xD;
          4. Has hypersensitivity to F 18 T807 or any of its excipients.&#xD;
&#xD;
          5. Contraindications to PET, PET-CT or MR (e.g. electronic medical devices, inability to&#xD;
             lie still for long periods) that make it unsafe for the individual to participate.&#xD;
&#xD;
          6. Severe claustrophobia.&#xD;
&#xD;
          7. Currently pregnant or breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tammie Benzinger, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ly CV, Koenig L, Christensen J, Gordon B, Beaumont H, Dahiya S, Chen J, Su Y, Nelson B, Jockel-Balsarotti J, Drain C, Jerome G, Morris JC, Fagan AM, Harms MB, Benzinger TLS, Miller TM, Ances BM. Tau positron emission tomography imaging in C9orf72 repeat expansion carriers. Eur J Neurol. 2019 Sep;26(9):1235-1239. doi: 10.1111/ene.13940. Epub 2019 Mar 25.</citation>
    <PMID>30790403</PMID>
  </results_reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 7, 2015</study_first_submitted>
  <study_first_submitted_qc>April 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2015</study_first_posted>
  <last_update_submitted>September 17, 2020</last_update_submitted>
  <last_update_submitted_qc>September 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Tammie L. S. Benzinger, MD, PhD</investigator_full_name>
    <investigator_title>Professor of Radiology and Neurological Surgery</investigator_title>
  </responsible_party>
  <keyword>fronto-temporal dementia</keyword>
  <keyword>Tauopathies</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Neurodegenerative Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We will share the data with other researchers. They may be doing research in areas similar to this research or in other unrelated areas. These researchers may be at Washington University, at other research centers and institutions, or industry sponsors of research. We may also share this research data with large data repositories (a repository is a database of information) for broad sharing with the research community. If the individual research data is placed in one of these repositories only qualified researchers, who have received prior approval from individuals that monitor the use of the data, will be able to look at the information.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT02414230/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

